Table 2.

A priori and observed correlations between PROMIS measures and myositis outcome measures

	n	Consensus exercise, % agreement voting members (n=14)	A priori hypothesi s for expected correlation	Observe correlation		Hypothesis confirmed?
	n	Consensus exercise, % agreement voting members (n=14)	A priori hypothesi s for expected correlation	Strength^*	r (95% CI)	Hypothesis confirmed?

PROMIS Pain Interference
Age	129	14/14 (100%)	weak	weak	−0.14 (−0.3–0.03)	Yes
Patient global	104	11/14 (79%)	moderate	moderate	0.46 (0.3–0.6)	Yes
Physician global	114	13/14 (93%)	weak	weak	0.34 (0.2–0.5)	Yes
MMT	114	14/14 (100%)	weak	weak	−0.21 (−0.4–0.0)	Yes
Creatine kinase	128	14/14 (100%)	weak	weak	0.01 (−0.2–0.2)	Yes
HAQ-DI	40	10/14 (71%)	modeate	weak	0.29 (0.0–0.6)^†	No
PROMIS Fatigue
Age	135	14/14 (100%)	weak	weak	−0.16 (−0.3–0.0)	Yes
Patient global	108	13/14 (93%)	moderate	moderate	0.54 (0.4–0.7)	Yes
Physician global	118	14/14 (100%)	weak	moderate	0.51 (0.4–0.6)	No
MMT	913	8/14 (57%)	weak	moderate	−0.41 (−0.5– −0.2)	N/A
Creatine kinase	4	10/14 (71%)	weak	weak	0.2 (0.0–0.4)	Yes
HAQ-DI	43	11/14 (79%)	moderate	moderate	0.55 (0.3–0.7)^†	Yes
PROMIS Physical Function
Age	129	13/14 (93%)	weak	weak	0.04 (−0.1–0.2)	Yes
Patient global	104	10/14 (71%)	moderate	moderate	−0.64 (−0.7– −0.5)	Yes
Physician global	114	11/14 (79%)	weak	moderate	−0.56 (−0.7– −0.4)	No
MMT	114	13/14 (93%)	moderate	moderate	0.49 (0.3–0.6)	Yes
Creatine kinase	128	9/14 (64%)	weak	weak	−0.18 (−0.3–0.0)	N/A
HAQ-DI	40	8/14 (57%)	moderate	strong	−0.83 (−0.9– −0.7)^†	N/A

Creatine kinase = log of creatine kinase activity/upper limit of normal; CI: confidence interval; HAQ-DI: Health Assessment Questionnaire Disability Index; MMT: Manual muscle testing; N/A: not applicable, a priori consensus not reached so hypothesis not able to be confirmed

Cutoffs for interpretation were <0.4, 0.4–0.7, and >0.7 for weak, moderate, and strong correlations

^†

Spearman correlation